31.19
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Bank of New York Mellon Corp - Defense World
How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Access to Community - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - jammulinksnews.com
Is Xenon Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
What drives Xenon Pharmaceuticals Inc. stock priceHigh-octane financial growth - jammulinksnews.com
What analysts say about Xenon Pharmaceuticals Inc. stockRapid profit acceleration - jammulinksnews.com
Mutual of America Capital Management LLC Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Smart Money Stock Analysis - Newser
(XENE) Investment Analysis and Advice - news.stocktradersdaily.com
Teacher Retirement System of Texas Reduces Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionReliable High Profit Alerts - Newser
What makes Xenon Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely - Yahoo Finance
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
How to Take Advantage of moves in (XENE) - news.stocktradersdaily.com
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Xenon Appoints CEO Ian Mortimer as Interim CFO - The Globe and Mail
XENE CEO Named Interim CFO After Sherry Aulin Resigns | XENE SEC FilingForm 8-K - Stock Titan
Xenon Pharmaceuticals Inc.(NasdaqGM:XENE) added to Russell Small Cap Comp Growth Index - MarketScreener
Xenon Pharmaceuticals: Riding the Russell Wave to Institutional Inflows and Clinical Milestones? - AInvest
Xenon Joins the Russell 3000® and Russell 2000® Indexes - The Manila Times
Xenon Pharmaceuticals added to Russell 3000 and 2000 indexes - Investing.com India
Xenon Pharmaceuticals Inc. Added to Russell 3000® and Russell 2000® Indexes in Annual Reconstitution - Quiver Quantitative
Xenon Pharmaceuticals Announces Equity Inducement Grants to New Employees - TipRanks
Is Xenon Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer - The Globe and Mail
Long Term Trading Analysis for (XENE) - news.stocktradersdaily.com
Xenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of “Buy” from Analysts - Defense World
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $57 - 富途牛牛
Xenon Pharmaceuticals price target raised to $57 from $55 at RBC Capital - Investing.com Canada
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk - MarketScreener
Cantor Fitzgerald Estimates XENE FY2026 Earnings - MarketBeat
Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Xenon Pharmaceuticals at Goldman Sachs Conference: Strategic Clinical Advances By Investing.com - Investing.com Canada
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):